Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorYunfeng Xia
About this trial
Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.
Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.
Eligibility criteria
Qualifiers
Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.
Disqualifiers
Patients with communication barriers or other conditions that prevent them from cooperating with the study.
Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
Patients who are not willing to actively cooperate with the study.
Patients with severe liver cirrhosis, active tuberculosis and AIDS.
Trial design
Treatments tested in this trial
- APP-based management
Treatment groups
392 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yunfeng Xia
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Sponsor institution
Source ClinicalTrials.gov